

**Keywords:** cancer prevention; HbA<sub>1c</sub>; diabetes; cancer risk; pre-diabetes; hyperglycaemia

# Does cancer risk increase with HbA<sub>1c</sub>, independent of diabetes?

J C de Beer<sup>1</sup> and L Liebenberg<sup>\*,1,2</sup>

<sup>1</sup>Center for Research and Continued Engineering Development, North-West University (Pretoria Campus), Suite No. 91, Private Bag X30, Lynnwood Ridge, Pretoria 0040, South Africa and <sup>2</sup>TEMM International (Pty) Ltd, Pretoria, South Africa

**Background:** The risks for several cancer types are increased in people with diabetes. Hyperglycaemia, hyperinsulinaemia, inflammation and altered hormonal concentrations are common characteristics between the two diseases and can all be linked to hyperglycaemia.

**Methods:** Here, we use glycated haemoglobin (HbA<sub>1c</sub>) as a biomarker for chronic hyperglycaemia. We explore whether cancer risk increases with HbA<sub>1c</sub>, independent of diabetes, and, therefore, if risk is already increased below the diabetic HbA<sub>1c</sub> range, by analysing data from current studies linking HbA<sub>1c</sub> to risk of several cancer types.

**Results:** The data reveal that chronic hyperglycaemia correlates with increased cancer risk for a number of cancers, except prostate cancer. Evidence is also provided that risk is already increased in the pre-diabetic and normal ranges for several cancers.

**Conclusions:** These results merit urgent investigation into the risks and advantages of updating recommendations for stricter glycaemic control in diabetic and non-diabetic subjects, as this could help reduce the risk of cancer incidence and mortality.

People with established diabetes have an increased risk of developing certain cancer types compared with non-diabetics; the strongest associations are seen for endometrial, liver and pancreatic cancer, followed by kidney, oesophageal, colorectal, breast and bladder cancer, and leukaemia (Giovannucci *et al*, 2010; Habib and Rojna, 2013). It is, however, not clear whether hyperglycaemia, a hallmark of diabetes, correlates with increased cancer risk *independent of diabetes*. If such an association exists, then the cancer risk in persons with glucose levels lower than that required to diagnose diabetes might already be increased. This would have important diagnostic and therapeutic ramifications, which we investigate here.

Research surrounding the increasing prevalence of cancer and diabetes (Mathers and Loncar, 2006; Giovannucci *et al*, 2010; World Health Organization, 2010; Wagner and Brath, 2012) has established direct pathogenetic commonalities between these two chronic diseases. These include hyperinsulinaemia, hyperglycaemia, inflammation and altered concentrations of endogenous hormones.

The association of most cancers and diabetes with chronic inflammation (Pollak, 2012; Coussens *et al*, 2013) and the

direct link between increased inflammatory signalling and high blood glucose levels in cancer models (Habib and Rojna, 2013) support the possibility that chronic hyperglycaemia may have a pivotal role in cancer risk in humans. Increased production of endogenous hormones can also be indirectly linked to hyperglycaemia via hyperinsulinaemia and obesity, and, therefore, also to diabetes and cancer risk (Montaruli *et al*, 2012; Patterson *et al*, 2013; Robien *et al*, 2013). Chronic hyperglycaemia in diabetes patients seems to be directly linked with the ubiquitous reliance of most cancer cells on high glucose flux (Hanahan and Weinberg, 2011; Mathews and Liebenberg, 2013). Onodera *et al* (2014) found that an increase in glucose uptake can activate oncogenic pathways in breast cells. This could potentially provide another pathway by which hyperglycaemia increases cancer incidence risk.

Chronic hyperglycaemia may be evaluated by measuring glycated haemoglobin (HbA<sub>1c</sub>) (American Diabetes Association, 2013), a biomarker of the average blood glucose concentration for a prolonged period of time (Travier *et al*, 2007; Habib and Rojna, 2013). Importantly, HbA<sub>1c</sub> may also be a good indicator of metabolic processes influencing levels of insulin (Saydah *et al*, 2003)

\*Correspondence: Professor L Liebenberg; E-mail: lliebenberg@researchtoolbox.com

Received 18 November 2013; revised 24 February 2014; accepted 26 February 2014; published online 27 March 2014

© 2014 Cancer Research UK. All rights reserved 0007–0920/14

or insulin-like growth factors, important for cancer pathogenesis (Habib and Rojna, 2013).

Most studies focus on the association between cancer risk and diabetes. This approach, however, does not provide evidence for the potential causal links between the two diseases (Giovannucci *et al*, 2010).

One study (Pisani, 2008) performed a meta-analysis on epidemiological studies linking hyperglycaemia and risk for colorectal and pancreatic cancers. The researcher only assessed risk in the highest compared with the lowest categories of exposure. Another study (Johnson and Bowker, 2011) performed a meta-analysis on the impact of glycaemic control in type 2 diabetic patients and found no decrease in cancer risk with increased glycaemic control. This meta-analysis may have been influenced by confounding factors such as insulin usage, which could increase cancer risk (Pollak, 2012). Habib and Rojna (2013) reviewed some of the most important studies on the association between cancer risk and hyperglycaemia. They, however, did not attempt to consolidate the evidence per cancer type or provide a dose-response relation.

No meta-analysis has yet been published that consolidates risk of different types of cancers with different HbA<sub>1c</sub> ranges, including glycaemic levels lower than that associated with diabetes. If cancer risk is lower at low HbA<sub>1c</sub> levels, then the incidence of cancer in the diabetic and non-diabetic populations could potentially be lowered by decreasing glucose levels. This could be achieved by means of appropriate lifestyle or therapeutic interventions, and by imposing stricter recommendations for glycaemic control.

Here, we perform dose-response meta-analyses on the current published evidence regarding HbA<sub>1c</sub> levels and risk of various cancers. This *post hoc* analysis attempts to establish whether cancer risk is already elevated in normal and pre-diabetic HbA<sub>1c</sub> ranges. The overall goal is to determine whether HbA<sub>1c</sub> concentrations can effectively quantify cancer risk *independent of diabetes*.

## MATERIALS AND METHODS

**Study selection.** Only English-language articles were included. Studies from 1960 to the present (date last searched – 9 January 2014) were included in the search. Articles using the following risk measures were included: relative risk (RR), odds ratio (OR) or hazard ratio (HR). For studies to be included in the quantitative meta-analysis, they had to provide risk data for at least three HbA<sub>1c</sub> levels. Literature searches were performed using Science Direct and Scopus to identify articles that relate HbA<sub>1c</sub> to the risk of cancer incidence (primary or recurrence) or mortality. More articles were identified from the reference lists of surveyed articles.

Search terms included a number of MeSH terms and were combinations of the following: ('cancer' OR 'malignancy' OR 'tumor' OR 'tumour' OR 'neoplasm' OR 'neoplasia') AND ('hemoglobin a1c' OR 'hba1c' OR 'glycated hemoglobin' OR 'glycosylated hemoglobin' OR 'a1c' OR 'haemoglobin a1c' OR 'glycated haemoglobin' OR 'glycosylated haemoglobin' OR 'glycohemoglobin a' OR 'glycohaemoglobin a') in the title of the study.

The trends adjusted for the most confounding variables were used, where sufficient information was available on that trend. This was done so that the effects of most of the potential confounders could be adjusted for. This may, however, have increased the heterogeneity between studies, as not all studies adjusted for the same confounders. Only studies providing data on specific cancer types were included (not studies referring to cancer in general).

It was assumed that all studies used the National Glycohemoglobin Standardization Program (NGSP) HbA<sub>1c</sub> reference, unless

explicitly stated otherwise in a specific study. Suitable conversion to the NGSP reference was performed for three studies (Stocks *et al*, 2007, 2008; Cust *et al*, 2009) that used the Swedish monoS standard, using the relation  $\text{NGSP (\%)} = (\text{monoS} + 0.8925)/0.9718$ . Using the NGSP reference, 'diabetes' is deemed to exist at HbA<sub>1c</sub> levels greater than 6.5% (American Diabetes Association, 2013); 'pre-diabetes' if HbA<sub>1c</sub> levels are between 5.7% and 6.4% (American Diabetes Association, 2013). The 'normal glycaemic' range is taken to span from ~4–5.7% (American Diabetes Association, 2013).

**Data extraction.** The following data were extracted from the studies: reference details, number of cases per HbA<sub>1c</sub> level for OR, RR and HR, number of controls per HbA<sub>1c</sub> level for OR, total number of persons per HbA<sub>1c</sub> level for RR, number of person-years per HbA<sub>1c</sub> level for HR, gender, cancer site, whether the risk was measured in RR, OR or HR, the risk per HbA<sub>1c</sub> range, HbA<sub>1c</sub> range or level and the 95% confidence intervals (CIs) per HbA<sub>1c</sub> level. Additional information was obtained from the authors of two studies to be able to include these studies in the quantitative analysis.

**Statistical analyses.** When a range of HbA<sub>1c</sub> values was provided, a single value was chosen per HbA<sub>1c</sub> category using method 1 in Hartemink *et al* (2006). It is acknowledged that the method that is used to select a single value per dose-response category could potentially affect the outcome (Hartemink *et al*, 2006). The method works as follows. Where a range was specified for a dose, the midpoint of the range was selected as the point representing that range; where an open-ended range was specified, the dose for the lower open-ended range was calculated by subtracting half of the width of the second lowest range from the lowest value specified (the top value of the bottom open-ended range) (Hartemink *et al*, 2006); the dose for the upper open-ended range was calculated by adding the width of the second highest range to the highest value specified (bottom value of the upper open-ended range) (Hartemink *et al*, 2006).

Dose-response meta-analyses were performed per cancer type and for cancer incidence and mortality separately using the *dosresmeta* R package (Crippa, 2013; R Core Team, 2013). This is the R-equivalent of the *GLST* Stata-module developed by Orsini *et al* (2006, 2012).

Risk estimates were transformed using the natural logarithm (*ln*). The reference HbA<sub>1c</sub> level per study was subtracted from each HbA<sub>1c</sub> level in the study, resulting in a model fitted through the origin (i.e., no intercept).

Linear and restricted cubic spline (RCS) models (with three knots, located at the 10th, 50th and 90th percentiles of the data) of the natural logarithm-transformed risk estimates were developed using random-effects meta-analysis methods, to incorporate heterogeneity. If, for a certain cancer type, only a single study was available, and that study had fewer than six exposure levels, only a linear model was fitted, as the function that develops the RCS models requires at least six data points. The graphical displays of the statistically significant models obtained during the analyses were referenced to the lowest HbA<sub>1c</sub> level for all the studies included in a model.

To assess non-linearity, the null hypothesis that the coefficient of the second spline is zero was tested. A significance level of  $P < 0.05$  was used.

Lack of goodness of fit and heterogeneity was determined by assessing whether the *P*-value from the chi-squared test was smaller than 0.1.  $I^2$  values were determined for each model.

Combined and separate models for RR, OR and HR were developed to assess whether the risk measure, and in effect the type of study, could influence the results.

RESULTS

The study selection process is illustrated in Figure 1. Thirty-six studies were identified through database searching. Thirty-two studies were identified from the reference lists of surveyed articles. Two duplicate studies were removed. The remaining 66 records were screened. Ten articles were not relevant to the study aims (e.g., they did not address cancer). For six of the records, full-text articles were not available or referred to conference abstracts. Fifty full-text articles were assessed. Of these, 18 articles were excluded as they either did not provide data on a specific cancer type (9 studies), they did not provide data on cancer (2 studies) or they used glycaemic measures other than HbA<sub>1c</sub> (7 studies). Thirty-two studies remained that were relevant for the qualitative synthesis. Eighteen studies were excluded from the quantitative analysis as they did not provide information on cancer incidence or mortality, but rather on stage or grade of cancer (4 studies), they provided information on cancer pre-cursors, such as adenoma, adenomatous polyps or benign neoplasia (5 studies), they did not provide data on RR, OR or HR (2 studies), they specified fewer than three HbA<sub>1c</sub> ranges (4 studies), the study population was already included in another study (2 studies) or enough information on the number of cases or person-years per HbA<sub>1c</sub> level was not available (1 study). Fourteen studies remained that were included in the quantitative meta-analyses. Of these, thirteen studies provided data on cancer incidence only, while one study provided data on cancer incidence as well as mortality (Joshu *et al*, 2012).

The statistically significant or border-line significant models that were obtained during the dose-response analyses are shown in

Figures 2–8. The plots are referenced to the lowest HbA<sub>1c</sub> level in the studies included in each model.

Female genital cancer

**Quantitative analysis.** Two studies (Travier *et al*, 2007; Miao Jonasson *et al*, 2012) on female genital cancer incidence were included in the quantitative analysis. Both used the HR as a risk measure. No statistically significant models were obtained in the analysis ( $P=0.2961$  for increasing log-linear model,  $P_{non-linearity}=0.3274$  for increasing-decreasing RCS model).




Figure 2. Relationship between risk for breast cancer incidence and HbA<sub>1c</sub>.




Figure 1. Flow diagram showing the study selection process (Moher *et al*, 2009).




Figure 3. Relationship between risk for colorectal cancer incidence and HbA<sub>1c</sub>.




Figure 4. Relationship between risk for colorectal cancer mortality and HbA<sub>1c</sub>.




Figure 5. Relationship between risk for gastric cancer incidence and HbA<sub>1c</sub>.

**Qualitative analysis.** Travier *et al* (2007) found a statistically significant (HR = 2.84, 95% CI = 1.35–5.98) increased risk in the 6% to 7% HbA<sub>1c</sub> range, compared with the reference risk in the <6% range. The risk was also increased in the >7% range, but not significantly (HR = 2.01, 95% CI = 0.69–5.89). Miao Jonasson *et al* (2012) found no statistically significant associations for cancer risk in the baseline (slightly decreased HRs) or updated mean (slightly increased HRs) HbA<sub>1c</sub> groups for a group of people with




Figure 6. Relationship between risk for pancreatic cancer incidence and HbA<sub>1c</sub>.




Figure 7. Relationship between risk for prostate cancer incidence and HbA<sub>1c</sub>.




Figure 8. Relationship between risk for respiratory cancer incidence (including lung cancer) and HbA<sub>1c</sub>.

type 2 diabetes. Levran *et al* (1984) revealed an increased number of endometrial cancer cases with HbA<sub>1c</sub> above 6.5%, as compared with below 6.5%. The distribution of controls was more even across all of the HbA<sub>1c</sub> ranges. They, however, did not provide risk measures for comparison. Levitan *et al* (2008) found no statistically significant trend ( $P = 0.53$ ) for uterine or ovarian cancer mortality risk. Stevens *et al* (2012) found some evidence of increased endometrial cancer stage with increasing HbA<sub>1c</sub>, but this was not statistically significant ( $P = 0.07$ ).



## Liver cancer

**Quantitative analysis.** One study (Travier *et al*, 2007) was included in the quantitative analysis for liver cancer incidence. The increasing log-linear HR model obtained from this study was not statistically significant ( $P=0.5737$ ).

**Qualitative analysis.** Two studies that were excluded from the quantitative analysis as they did not provide enough HbA<sub>1c</sub> levels (Donadon *et al*, 2010; Kaneda *et al*, 2012) found changes in hepatocellular carcinoma (HCC) risk as HbA<sub>1c</sub> increased. Kaneda *et al* (2012) found a large risk ( $HR=3.551$ ,  $P=0.03$ ) for HCC recurrence as the HbA<sub>1c</sub> level increased above 6.5% for patients with diabetes. Donadon *et al* (2010) found that the OR for HCC increased by 1.508 for each percentage increase in HbA<sub>1c</sub> for type 2 diabetic patients compared with controls with liver cirrhosis ( $P=0.0005$ ). Compared with the normal control group, the OR increased by 1.265 per 1% increase in HbA<sub>1c</sub> – this was, however, not statistically significant ( $P=0.1172$ ).

## Pancreatic cancer

**Quantitative analysis.** One study (Grote *et al*, 2011) was included in the quantitative analysis. The OR increasing log-linear model, including diabetic participants, was statistically significant ( $P=0.0049$ ). The increasing log-linear model, excluding diabetic participants, was also statistically significant ( $P=0.0148$ ).

**Qualitative analysis.** Another study (Levitan *et al*, 2008) found no statistically significant trends for pancreatic cancer mortality ( $P=0.40$ ), with decreased risk ( $RR=0.86$ ) in the lower normal HbA<sub>1c</sub> range of 4.88–5.08% and increased risk ( $RR=1.36$ ) in the upper normal range (5.09–5.59%), compared with the reference group (2.27–4.87%).

## Prostate cancer

**Quantitative analysis.** Four studies were included in the quantitative analysis for prostate cancer incidence (Stocks *et al*, 2007; Travier *et al*, 2007; Joshi *et al*, 2012; Miao Jonasson *et al*, 2012), while only one study (Joshi *et al*, 2012) was included in the analysis for mortality. The OR decreasing log-linear model obtained from the Stocks *et al* (2007) study was border-line statistically significant ( $P=0.0596$ ), while none of the other models were statistically significant ( $P=0.1114$  for the decreasing combined log-linear model,  $P=0.1783$  for the decreasing HR log-linear model,  $P=0.6502$  for the decreasing HR mortality log-linear model).

**Qualitative analysis.** Rusu *et al* (2011) found that HbA<sub>1c</sub> was statistically significantly ( $P=0.0001$ ) lower in patients with prostate cancer (HbA<sub>1c</sub>=6%) than in those without cancer (HbA<sub>1c</sub>=7.1%) or in patients with benign prostatic hyperplasia (HbA<sub>1c</sub>=7.4%). No adjustments were made for confounders in this study.

Kim *et al* (2010a) revealed statistically significant ( $P=0.001$ ) increased risks for higher pathological Gleason score cancer with increasing HbA<sub>1c</sub> level in a population of diabetic men. Hong *et al* (2009) found a significantly higher rate of high pathological Gleason score cancers ( $P=0.005$ ) and extraprostatic extension ( $P=0.043$ ) in diabetic men with HbA<sub>1c</sub> levels  $\geq 6.5\%$  than in those with HbA<sub>1c</sub> levels lower than 6.5%.

## Colorectal cancer

**Quantitative analysis.** Nine studies presented data on colorectal cancer incidence. Two of these studies (Platz *et al*, 1999; Khaw *et al*, 2004) were excluded from the quantitative analysis as they provided data from the same cohorts as other studies already

included. Seven studies remained that were included in the quantitative analysis ( $HR$  – Joshi *et al*, 2012;  $RR$  – Lin *et al*, 2005;  $OR$  – Rinaldi *et al*, 2008;  $OR$  – Saydah *et al*, 2003;  $OR$  – Stocks *et al*, 2008;  $HR$  – Travier *et al*, 2007;  $OR$  – Wei *et al*, 2005). One study also presented data on colorectal cancer mortality ( $HR$  – Joshi *et al*, 2012). The colorectal cancer incidence combined RCS model ( $P_{non-linearity}=0.0068$ ,  $P_{heterogeneity}=0.2046$ ,  $I^2=21.4\%$ ) and  $HR$  RCS model ( $P_{non-linearity}=0.0261$ ,  $P_{heterogeneity}=0.8494$ ,  $I^2=1\%$ ) both showed a decreased risk at lower HbA<sub>1c</sub> levels followed by an increased risk at higher HbA<sub>1c</sub> levels. The combined log-linear model ( $P=0.0325$ ,  $P_{heterogeneity}=0.1526$ ,  $I^2=33.2\%$ ) and  $OR$  log-linear model ( $P=0.0072$ ,  $P_{heterogeneity}=0.2945$ ,  $I^2=18.9\%$ ) both showed statistically significant increasing trends. The mortality RCS  $HR$  model was also statistically significant ( $P_{non-linearity}=0.0180$ ,  $P_{heterogeneity}=0.9849$ ,  $I^2=1\%$ ), with decreasing risk at lower HbA<sub>1c</sub> levels, and increasing risk at higher HbA<sub>1c</sub> levels. The other models were not statistically significant ( $P=0.3089$  for increasing  $HR$  log-linear model,  $P=0.1486$  for  $OR$  RCS decreasing-increasing model,  $P=0.3942$  for decreasing  $RR$  log-linear model).

**Qualitative analysis.** Further to the results from the dose-response relation, Khaw *et al* (2004) found a significantly increased risk as HbA<sub>1c</sub> increased in the combined ( $P<0.001$ ), men-only group ( $P<0.001$ ) and women-only group ( $P=0.03$ ). The risk in the women-only group was decreased in the 5–5.9% range ( $RR=0.7$ ), but increased above this range. Continuous analysis per 1% increase in HbA<sub>1c</sub> revealed an increase of  $RR=1.30$  for the combined group ( $P=0.02$ ),  $RR=1.35$  for the men-only group ( $P=0.02$ ) and  $RR=1.20$  for the women-only group ( $P=0.26$ ). The authors found that the increased risk for colorectal cancer in diabetic patients was largely due to the increase in HbA<sub>1c</sub> and not due to diabetes status. Platz *et al* (1999) and Siddiqui *et al* (2008a) found a significant increase in risk for advanced-stage colorectal cancer with higher HbA<sub>1c</sub> levels ( $P=0.02$  and  $P=0.002$ , respectively).

The risks for colorectal cancer pre-cursors (adenomatous and/or advanced adenomatous polyps) were significantly increased with increasing HbA<sub>1c</sub> levels in diabetic and non-diabetic subjects (Siddiqui *et al*, 2008b; Kim *et al*, 2010b). Hsu *et al* (2012) found an increase of  $OR=1.25$  in colorectal neoplasia for each percentage increase in HbA<sub>1c</sub> level for men and women ( $P=0.02$ ). HbA<sub>1c</sub> was not statistically significantly associated with colorectal adenoma, distal colorectal adenoma or advanced adenoma in two studies (Wei *et al*, 2006; Yang *et al*, 2010).

## Breast cancer

**Quantitative analysis.** Six studies on breast cancer incidence ( $HR$  – Joshi *et al*, 2012;  $HR$  – Miao Jonasson *et al*, 2012;  $HR$  – Travier *et al*, 2007;  $HR$  – Erickson *et al*, 2011;  $OR$  – Cust *et al*, 2009;  $RR$  – Lin *et al*, 2006) and one study on cancer mortality ( $HR$  – Joshi *et al*, 2012) were included in the quantitative analysis. A statistically significant RCS model for combined risk ( $P_{non-linearity}=0.0260$ ,  $P_{heterogeneity}=0.6457$ ,  $I^2=1\%$ ), which showed decreased risk at lower HbA<sub>1c</sub> levels and increased risk at higher HbA<sub>1c</sub> levels, as well as a border-line statistically significant increasing log-linear model for  $HR$  ( $P=0.0783$ ,  $P_{heterogeneity}=0.6948$ ,  $I^2=1\%$ ) was obtained. The other models were all statistically non-significant ( $P=0.2329$  for increasing combined log-linear model,  $P_{non-linearity}=0.3118$  for  $HR$  decreasing-increasing RCS model,  $P=0.2323$  for decreasing  $OR$  log-linear model,  $P_{non-linearity}=0.2844$  for increasing-decreasing RCS model,  $P=0.2007$  for decreasing  $RR$  log-linear model,  $P=0.1789$  for increasing  $HR$  log-linear mortality model).

**Qualitative analysis.** Two studies did not adjust for confounders and found contrasting results. Yadav *et al* (2012) observed that

HbA<sub>1c</sub> increased in pre- and post-menopausal breast cancer cases. Contrarily, Nemesure *et al* (2009) found decreased HbA<sub>1c</sub> in pre- and post-menopausal breast cancer cases.

Levitani *et al* (2008) found no statistically significant linear trend for breast cancer mortality with increasing HbA<sub>1c</sub> level ( $P = 0.23$ ).

#### Gastric cancer

**Quantitative analysis.** Two studies on gastric (stomach) cancer incidence were included in the quantitative analysis (HR – Ikeda *et al*, 2009; HR – Travier *et al*, 2007). The increasing log-linear trend obtained from these studies was statistically significant ( $P = 0.0171$ ,  $P_{\text{heterogeneity}} = 0.9439$ ,  $I^2 = 1\%$ ).

**Qualitative analysis.** No additional studies were available for discussion.

#### Respiratory cancer, including lung cancer

**Quantitative analysis.** Two studies on respiratory or lung cancer incidence were included in the quantitative analysis (HR – Joshi *et al*, 2012; HR – Travier *et al*, 2007). The RCS model obtained from these studies was statistically significant ( $P_{\text{non-linearity}} = 0.0353$ ,  $P_{\text{heterogeneity}} = 0.1537$ ,  $I^2 = 40.1\%$ ), with increasing risk at lower HbA<sub>1c</sub> levels, and decreasing risk at higher HbA<sub>1c</sub> levels. Neither the increasing log-linear HR mortality model ( $P = 0.1573$ ), nor the increasing-decreasing RCS HR mortality model from the Joshi *et al* (2012) study was statistically significant ( $P_{\text{non-linearity}} = 0.2996$ ).

**Qualitative analysis.** The Levitan *et al* (2008) study found increasing lung cancer mortality risk with increased HbA<sub>1c</sub> level, but the linear trend was not statistically significant ( $P = 0.22$ ).

#### Other cancers

**Quantitative analysis.** Results from other cancer types investigated were not statistically significant. These cancer types included lymphoma and leukaemia ( $P = 0.5427$  for the decreasing log-linear model), as well as melanoma ( $P = 0.5514$  for the increasing log-linear model). One study (HR – Travier *et al*, 2007) presented results on each type of cancer.

**Qualitative analysis.** Levitan *et al* (2008) found an increase in RR for lymphoma or leukaemia mortality as HbA<sub>1c</sub> increased. This was, however, not statistically significant ( $P = 0.18$  for a linear trend).

## DISCUSSION

**Quantitative analysis.** Results from the dose-response meta-analysis revealed the following statistically significant or borderline significant results:

- ✓ Increasing log-linear models for breast cancer (HR), colorectal cancer (OR and combined), gastric cancer (HR) and pancreatic cancer (OR).
- ✓ Decreasing log-linear model for prostate cancer (OR).
- ✓ Increased risk above 8.5% for breast cancer (combined) and colorectal cancer (HR for incidence and mortality), above 6.5% for colorectal cancer (combined) and increasing trend up to 7% and decreasing risk above 7% for respiratory cancer (HR).

The following relations were not statistically significant:

- ✓ Increasing log-linear models for female genital cancer (HR), liver cancer (HR), colorectal cancer (HR), breast cancer (combined and HR mortality), respiratory (HR) and melanoma (HR).

- ✓ Decreasing log-linear models for prostate cancer (combined, HR and HR mortality), colorectal (RR), breast (OR and RR) and lymphoma and leukaemia (HR).

**Qualitative analysis.** The qualitative analysis revealed some additional information. Cancer stage for female genital cancer was found to be non-significantly increased with increasing HbA<sub>1c</sub>. Liver cancer incidence increased significantly for diabetics and in patients with HbA<sub>1c</sub> above 6.5%. A significantly higher rate of high-grade prostatic tumours and extraprostatic extension was present with increasing HbA<sub>1c</sub>. For colorectal cancer, advanced stage colorectal cancer incidence and pre-cursor incidence increased with increasing HbA<sub>1c</sub> level. Respiratory/lung cancer, as well as lymphoma and leukaemia, mortality was non-significantly increased with increasing HbA<sub>1c</sub> level.

## CONCLUSIONS

Our study corroborates that cancer sites should be investigated separately, as the observed trends differ between cancer sites. Evidence is provided that indicates:

- ✓ Cancer incidence risk is already increased in the pre-diabetic and normal ranges for colorectal, gastric, pancreatic and respiratory cancers, although the results are not the same for all risk measures.
- ✓ Cancer incidence is higher at HbA<sub>1c</sub> levels in the diabetic range for colorectal, gastric, pancreatic, breast and liver cancers.

There is possible evidence for:

- ✓ Decreased risk of prostate cancer incidence with increasing HbA<sub>1c</sub> level, and already in the pre-diabetic and normal ranges.
- ✓ Increased risk of breast cancer incidence in the diabetic, pre-diabetic and normal ranges.

Our study reveals that chronic hyperglycaemia, as quantified by HbA<sub>1c</sub> levels, correlates with increased cancer risk in colorectal, gastric, liver and pancreatic cancers, and possibly breast cancer, while correlating with decreased prostate cancer risk. The relations for other cancer types investigated are not statistically significant. It is also clear that there is increased risk for higher cancer stage/grade and cancer pre-cursor incidence for some cancer types with increasing HbA<sub>1c</sub> level.

The near-linear association of HbA<sub>1c</sub> levels with risk of several cancers supports the conjecture that it might be possible to use HbA<sub>1c</sub> as an independent metabolic biomarker for cancer risk in diabetic or non-diabetic persons. Significantly, the study also provides preliminary evidence for an already increased cancer risk in the normal and pre-diabetic categories for a number of cancers. The incidence of cancer in the diabetic and non-diabetic populations could, therefore, potentially be reduced by decreasing glucose levels. This could be achieved by means of appropriate lifestyle or therapeutic interventions, and by imposing stricter recommendations for glycaemic control (Krone and Ely, 2005).

The risks and advantages of updating recommendations for stricter glycaemic control (in diabetic and non-diabetic subjects) merit urgent investigation. Indications are that such stricter glycaemic control measures could help reduce the risk for cancer incidence and mortality (Krone and Ely, 2005) as long as care is taken to ensure that stricter glycaemic control does not result in hypoglycaemia, which may have other deleterious effects.

## ACKNOWLEDGEMENTS

This work was supported by TEMM International (Pty) Ltd. We would like to thank Professor Eugene Fine (Albert Einstein College of Medicine) for his valuable comments and suggestions.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## REFERENCES

- American Diabetes Association (2013) Standards of medical care in diabetes - 2013. *Diabetes Care* **36**(Suppl 1): S11–S66.
- Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumor-promoting chronic inflammation: a magic bullet. *Science* **339**(6117): 286–291.
- Crippa A (2013) Dosresmeta: Performing dose-response meta-analysis, computer software, <http://cran.r-project.org/web/packages/dosresmeta/index.html>.
- Cust AE, Stocks T, Lukanova A, Lundin E, Hallmans G, Kaaks R, Jonsson H, Stattin P (2009) The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. *Breast Cancer Res Treat* **113**(3): 567–576.
- Donadon V, Balbi M, Valent F, Avogaro A (2010) Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. *World J Gastroenterol* **16**(24): 3025–3032.
- Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, Laughlin GA, Saquib N, Rock CL, Pierce JP (2011) Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. *J Clin Oncol* **29**(1): 54–60.
- Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. *Diabetes Care* **33**(7): 1674–1685.
- Grote VA, Rohrmann S, Nieters A, Dossus L, Tjønneland A, Halkjær J, Overvad K, Fagherazzi G, Boutron-Ruault MC, Morois S, Teucher B, Becker S, Sluik D, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Pala V, Tumino R, Vineis P, Panico S, Rodríguez L, Duell EJ, Molina-Montes E, Dorronsoro M, Huerta JM, Ardanaz E, Jeurink SM, Beulens JW, Peeters PH, Sund M, Ye W, Lindkvist B, Johansen D, Khaw KT, Wareham N, Allen N, Crowe F, Jenab M, Romieu I, Michaud DS, Riboli E, Romaguera D, Bueno-de-Mesquita HB, Kaaks R (2011) Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Diabetologia* **54**(12): 3037–3046.
- Habib SL, Rojina M (2013) Diabetes and risk of cancer. *ISRN Oncol* **2013**: 583786.
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* **144**(5): 646–674.
- Hartemink N, Boshuizen HC, Nagelkerke NJ, Jacobs MA, van Houwelingen HC (2006) Combining risk estimates from observational studies with different exposure cutpoints: a meta-analysis on body mass index and diabetes type 2. *Am J Epidemiol* **163**(11): 1042–1052.
- Hong SK, Lee ST, Kim SS, Min KE, Byun SS, Cho SY, Choe G, Lee SE (2009) Significance of preoperative HbA<sub>1c</sub> level in patients with diabetes mellitus and clinically localized prostate cancer. *Prostate* **69**(8): 820–826.
- Hsu YC, Chiu HM, Liou JM, Chang CC, Lin JT, Liu HH, Wu MS (2012) Glycated hemoglobin A<sub>1c</sub> is superior to fasting plasma glucose as an independent risk factor for colorectal neoplasia. *Cancer Causes Control* **23**(2): 321–328.
- Ikeda F, Doi Y, Yonemoto K, Ninomiya T, Kubo M, Shikata K, Hata J, Tanizaki Y, Matsumoto T, Iida M, Kiyohara Y (2009) Hyperglycemia increases risk of gastric cancer posed by *Helicobacter pylori* infection: a population-based cohort study. *Gastroenterology* **136**(4): 1234–1241.
- Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. *Diabetologia* **54**(1): 25–31.
- Joshu CE, Prizment AE, Dlugiewski PJ, Menke A, Folsom AR, Coresh J, Yeh HC, Brancati FL, Platz EA, Selvin E (2012) Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) study, 1990–2006. *Int J Cancer* **131**(7): 1667–1677.
- Kaneda K, Uenishi T, Takemura S, Shinkawa H, Urata Y, Sakae M, Yamamoto T, Kubo S (2012) The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virus-related hepatocellular carcinoma. *J Surg Oncol* **105**(6): 606–611.
- Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European Prospective Investigation into Cancer - Norfolk Study. *Cancer Epidemiol Biomarkers Prev* **13**(6): 915–919.
- Kim HS, Presti Jr JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ (2010a) Glycemic control and prostate cancer progression: results from the SEARCH database. *Prostate* **70**(14): 1540–1546.
- Kim BJ, Kim YH, Sinn DH, Kang KJ, Kim JY, Chang DK, Son HJ, Rhee PL, Kim JJ, Rhee JC (2010b) Clinical usefulness of glycosylated hemoglobin as a predictor of adenomatous polyps in the colorectum of middle-aged males. *Cancer Causes Control* **21**(6): 939–944.
- Krone CA, Ely JTA (2005) Controlling hyperglycemia as an adjunct to cancer therapy. *Integr Cancer Ther* **4**(1): 25–31.
- Levitin EB, Liu S, Stampfer MJ, Cook NR, Rexrode KM, Ridker PM, Buring JE, Manson JE (2008) HbA<sub>1c</sub> measured in stored erythrocytes and mortality rate among middle-aged and older women. *Diabetologia* **51**(2): 267–275.
- Levrin D, Modan M, Mencer J, Dulitzky M (1984) Increased rate of glucose intolerance in endometrial cancer - a community-based study. *Gynecol Obstet Invest* **18**(4): 190–193.
- Lin J, Ridker PM, Pradhan A, Lee IM, Manson JE, Cook NR, Buring JE, Zhang SM (2005) Hemoglobin A<sub>1c</sub> concentrations and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev* **14**(12): 3010–3012.
- Lin J, Ridker PM, Rifai N, Lee IM, Manson JE, Buring JE, Zhang SM (2006) A prospective study of hemoglobin A<sub>1c</sub> concentrations and risk of breast cancer in women. *Cancer Res* **66**(5): 2869–2875.
- Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* **3**(11): 2011–2030.
- Mathews EH, Liebenberg L (2013) Short-term starvation for cancer control in humans. *Exp Gerontol* **48**(11): 1293.
- Miao Jonasson J, Cederholm J, Eliasson B, Zethelius B, Eeg-Olofsson K, Gudbjörnsdóttir S (2012) HbA<sub>1c</sub> and cancer risk in patients with type 2 diabetes - a nationwide population-based prospective cohort study in Sweden. *PLoS One* **7**(6): e38784.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* **151**(4): 264–269.
- Montaruli A, Patrini P, Roveda E, Carandente F (2012) Physical activity and breast cancer. *Sport Sci Health* **8**(1): 1–13.
- Nemesure B, Wu SY, Hambleton IR, Leske MC, Hennis AJ, Barbados National Cancer Study Group (2009) Risk factors for breast cancer in a black population - The Barbados National Cancer Study. *Int J Cancer* **124**(1): 174–179.
- Onodera Y, Nam JM, Bissell MJ (2014) Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. *J Clin Invest* **124**(1): 367–384.
- Orsini N, Bellocco R, Greenland S (2006) Generalized least squares for trend estimation of summarized dose-response data. *Stata J* **6**(1): 40–57.
- Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D (2012) Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. *Am J Epidemiol* **175**(1): 66–73.
- Patterson RE, Rock CL, Kerr J, Natarajan L, Marshall SJ, Pakiz B, Cadmus-Bertram LA (2013) Metabolism and breast cancer risk: frontiers in research and practice. *J Acad Nutr Diet* **113**(2): 288–296.
- Pisani P (2008) Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. *Arch Physiol Biochem* **114**(1): 63–70.
- Platz EA, Hankinson SE, Rifai N, Colditz GA, Speizer FE, Giovannucci E (1999) Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). *Cancer Causes Control* **10**(5): 379–386.
- Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. *Nat Rev Cancer* **12**(3): 159–169.
- R Core Team (2013) R: A language and environment for statistical computing, computer software, <http://www.R-project.org/>.
- Rinaldi S, Rohrmann S, Jenab M, Biessy C, Sieri S, Palli D, Tumino R, Mattiello A, Vineis P, Nieters A, Linseisen J, Pischon T, Boeing H, Hallmans G, Palmqvist R, Manjer J, Wirfält E, Crowe FL, Khaw KT,



- Bingham S, Tjønneland A, Olsen A, Overvad K, Lund E, Skeie G, Clavel-Chapelon F, Boutron-Ruault MC, de Lauzon-Guillain B, Ardanaz E, Jakšzyn P, Ramon Quiros J, Chirlaque MD, Sanchez MJ, Dorransoro M, Trichopoulou A, Lagiou P, Trichopoulos D, Bueno-de-Mesquita HB, van Duijnhoven FJ, Peeters PH, Slimani N, Ferrari P, Byrnes GB, Riboli E, Kaaks R (2008) Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev* **17**(11): 3108–3115.
- Robien K, Rock CL, Demark-Wahnefried W (2013) Nutrition and cancers of the breast, endometrium, and ovary. In: *Nutrition in the Prevention and Treatment of Disease*, Coulston AM, Boushey CJ, Ferruzzi MG (eds) pp 657–672. Elsevier: London.
- Rusu F, Rusu E, Radulian G, Enache G, Jinga M, Rusu A, Jinga V, Codreanu O, Mischianu D, Cheta D (2011) Screening for prostatic tumors in metabolic syndrome patients in Romania. *Acta Endo* **7**(1): 47–58.
- Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ (2003) Association of markers of insulin and glucose control with subsequent colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* **12**(5): 412–418.
- Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B (2008a) Elevated HbA<sub>1c</sub> is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. *Dig Dis Sci* **53**(9): 2486–2494.
- Siddiqui AA, Maddur H, Naik S, Cryer B (2008b) The association of elevated HbA<sub>1c</sub> on the behavior of adenomatous polyps in patients with type-II diabetes mellitus. *Dig Dis Sci* **53**(4): 1042–1047.
- Stevens EE, Yu S, Van Sise M, Pradhan TS, Lee V, Pearl ML, Lee YC, Abulafia O (2012) Hemoglobin A<sub>1c</sub> and the relationship to stage and grade of endometrial cancer. *Arch Gynecol Obstet* **286**(6): 1507–1512.
- Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G, Kaaks R, Stattin P (2008) Components of the metabolic syndrome and colorectal cancer risk: a prospective study. *Int J Obes* **32**(2): 304–314.
- Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B, Hallmans G, Kaaks R, Stattin P (2007) Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. *Int J Cancer* **120**(12): 2678–2686.
- Travier N, Jeffreys M, Brewer N, Wright CS, Cunningham CW, Hornell J, Pearce N (2007) Association between glycosylated hemoglobin and cancer risk: a New Zealand linkage study. *Ann Oncol* **18**(8): 1414–1419.
- Wagner KH, Brath H (2012) A global view on the development of non communicable diseases. *Prev Med* **54**(Suppl): S38–S41.
- Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E (2005) A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev* **14**(4): 850–855.
- Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E (2006) C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. *Cancer Epidemiol Biomarkers Prev* **15**(4): 750–755.
- World Health Organization (2010) Global Status Report on Noncommunicable Diseases 2010.
- Yadav NK, Poudel B, Thanpari C, Chandra Koner B (2012) Assessment of biochemical profiles in premenopausal and postmenopausal women with breast cancer. *Asian Pac J Cancer Prev* **13**(7): 3385–3388.
- Yang YX, Habel LA, Capra AM, Achacoso NS, Quesenberry Jr CP, Ferrara A, Levin TR, Lewis JD (2010) Serial glycosylated hemoglobin levels and risk of colorectal neoplasia among patients with type 2 diabetes mellitus. *Cancer Epidemiol Biomarkers Prev* **19**(12): 3027–3036.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.